Numinus Bioscience adds research space,
enhances contract services,
accelerates IP development and increases psychedelic supply
capacity
VANCOUVER, BC, March 9, 2021 /CNW/ - Numinus Wellness Inc.
("Numinus" or the "Company") (TSXV: NUMI), a global leader in
supporting and expanding the safe, accessible and evidence-based
use of psychedelic-assisted psychotherapies (PAP), is pleased to
announce plans to significantly expand its psychedelics research
laboratory by late 2021.
A 7,500 square-foot expansion will be developed and housed in an
existing Numinus-leased building adjacent to the current lab. The
expansion announcement comes days after Numinus received amendments
to its federal licence under Canada's Controlled Drugs and Substances Act
to allow the possession, production, assembly, sale, export and/or
delivery of a variety of psychedelics including Ketamine, LSD,
Mescaline, N,N-Dimethyltryptamine (DMT), N-Methyl-3,4,
methylenedioxyamphetamine (MDMA), Psilocin and
Psilocybin.1
"Our investment in an expanded lab marks a key milestone for
Numinus and provides the necessary foundation for therapeutics
development and research infrastructure to advance
psychedelic-assisted psychotherapy in Canada and around the world," said
Sharan Sidhu, Science Officer and
General Manager for Numinus Bioscience, the Company's laboratory
division and a pioneer in psychedelic research and development.
Added Sidhu: "When complete, the facility will enhance our IP
and partnerships strategy, generate more revenue through analytics
testing for psychedelics and other contract services, and increase
our supply of consistent, safe and effective psychedelics for
clinical use and trials undertaken by academic, not-for-profit and
for-profit entities."
The current lab is conducting innovative work in areas such as
Psilocybe mushroom cultivation and extraction, formulation
studies and a genotypically verified spore bank and tissue culture
library. The expanded facility will accelerate this work and add
several psychedelic substances and capabilities to contract lab
services, increase capacity for high-throughput psychedelics
testing and enhance research and development activities in a wide
array of psychedelics.
While Numinus Bioscience develops infrastructure, systems and
processes at the expansion site, contract and research work will
continue uninterrupted at the Company's current Health
Canada-licensed laboratory facility.
Lab to receive $1.2 million
in new equipment
The current laboratory facility recently took possession of
next-generation analytical equipment including the Orbitrap
Exploris 120 Mass Spectrometer, a state-of-the-art high-resolution
mass spectrometry instrument that supports research to optimize the
cultivation, harvest and extraction of
Psilocybe mushrooms and implement discovery of unknowns
and interactions in several psychedelic botanicals in addition to
mushrooms. The lab expects to soon receive additional
instrumentation, representing a total investment of $1.2 million, to support innovation and
development of intellectual property related to Psilocybe
mushrooms and standardized test methods for a range of
psychedelics.
1Please
see Regulatory approvals place Numinus lab at the forefront of
global psychedelics research, March 4, 2021.
|
Note
The safety and efficacy of psychedelic-assisted
psychotherapy is currently under investigation. It has not yet been
approved by Health Canada or the U.S. FDA, does not work for
everyone, and carries risks even in therapeutic settings. These
statements are no guarantee of future Health Canada or FDA approval
or availability of psychedelic-assisted psychotherapy. These
statements necessarily involve known and unknown risks and
uncertainties, which may cause actual outcomes to differ materially
from projections.
About Numinus
Numinus Wellness Inc. (TSXV:NUMI) is a
health care and research company creating psychedelic-centred
solutions to treat mental illness, substance abuse and trauma.
Numinus Health delivers treatments through clinics
and virtual services, with clinics in Vancouver and Montreal.
Numinus R&D develops clinical and therapeutic
protocols to use in treatments, in collaboration with research
partners and regulators.
Numinus Bioscience develops formulations and methods for
a safe supply, using Health Canada licences, scientific expertise
and cutting-edge technology.
Learn more at numinus.ca, and follow us on Facebook, Twitter,
and Instagram.
Forward Looking Statements
This news release contains forward-looking statements within
the meaning of applicable securities laws. All statements that are
not historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, are "forward-looking statements."
Forward-looking statements can be identified by the use of words
such as "plans", "expects" or "does not expect", "is expected",
"estimates", "intends", "anticipates" or "does not anticipate", or
"believes", or variations of such words and phrases or statements
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward looking statements. Such risks and uncertainties include,
among others, dependence on obtaining and maintaining regulatory
approvals, including acquiring and renewing federal, provincial,
municipal, local or other licences and any inability to obtain all
necessary governmental approvals licences and permits to operate
and expand the Company's facilities; regulatory or political change
such as changes in applicable laws and regulations, including
federal and provincial legalization, due to inconsistent public
opinion, perception of the medical-use and adult-use marijuana
industry, bureaucratic delays or inefficiencies or any other
reasons; any other factors or developments which may hinder market
growth; the Company's limited operating history and lack of
historical profits; reliance on management; the Company's
requirements for additional financing, and the effect of capital
market conditions and other factors on capital availability;
competition, including from more established or better financed
competitors; and the need to secure and maintain corporate
alliances and partnerships, including with research and development
institutions, customers and suppliers; the development and
implementation of medical protocols and treatment standard
operating procedures for the use of psychedelic therapies; the
Company's goals to develop and implement partnerships with research
organizations and other key players in the integrative mental
health industry; the Company's ability to successfully withstand
the economic impact of COVID-19; the medical benefits, safety,
efficacy, dosing and social acceptance of psychedelics; the
approval and/or success of compassionate access clinical trials;
the cultivation and harvest of psilocybe mushrooms; and the
availability of trained personnel and medical professionals. These
factors should be considered carefully, and readers are cautioned
not to place undue reliance on such forward-looking statements.
Although the Company has attempted to identify important risk
factors that could cause actual actions, events or results to
differ materially from those described in forward-looking
statements, there may be other risk factors that cause actions,
events or results to differ from those anticipated, estimated or
intended. There can be no assurance that forward-looking statements
will prove to be accurate, as actual results and future events
could differ materially from those anticipated in forward-looking
statements. The Company has no obligation to update any
forward-looking statement, even if new information becomes
available as a result of future events, new information or for any
other reason except as required by law.
SOURCE Numinus Wellness Inc.